: + 86-21-6176-5100
Bone provides protection to visceral organs, storage of minerals, locomotive movement and are the locations of hematopoiesis. Structural integrity of bone can be affected by factors of aging, dietary imbalance, disuse, environmental contamination, infections, medicine, metabolic disorders, physical loading, radiation, smoking and trauma. Efficacy and safety data of the developing therapeutics to bone in animal models are required to predict the effects in human for excluding the toxicity of it.
Bone fragility increases with age in both genders, and most notably after menopause in female. Anti-resorptive agents are well established, such as bisphosphonates, SERMs and likely anti-RANKL antibodies. Anabolic agents are actively being developed. Besides PTH analogues and stem cells, molecules from BMP family and Wnt signal pathways, such as Smads, ERK, Dkk-1, Runx2, and beta-catenin are targets for therapeutics. Safety and efficacy data of bone in animal models (rodents and non-human primates) are required to predict the therapeutic effects in human.
At PharmaLegacy, our scientists have cumulated more than two centuries of experiences in bone physiopathology, especially in bone safety, metabolic bone diseases, osteoarthritis and osteoporosis. Our familiarity with IND/NDA and SOP driven GLP quality assurance operations can aid your regulatory submission.
Data from this model is being collected.
Please feel free to contact us if you are interested in it.
